Enfortumab vedotin in the treatment of urothelial cancers and beyond.

Abstract

Enfortumab vedotin (EV) is the first antibody-drug conjugate approved for locally advanced or metastatic urothelial cancers (la/mUCs), a disease group historically associated with limited prognosis and therapeutic options. EV consists of monomethyl auristatin E, a microtubule-disrupting agent linked to an antibody targeting Nectin-4. In clinical trials, EV demonstrated high response rates and superior survival in the third-line setting for la/mUC compared with chemotherapy. Peripheral neuropathy and rash were among the most common serious adverse events. EV is currently approved in multiple countries for the treatment of la/mUC in the later-line setting. Ongoing trials seek to expand the indication for EV and to study therapeutic combinations with other agents.

• Authors: Risa L Wong, Evan Y Yu
• Journal: Future oncology (London, England) (Future Oncol) Vol. 18 Issue 27 Pg. 3067-3084 (Sep 2022) ISSN: 1744-8301 [Electronic] England
• PMID: 36004667 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Immunoconjugates
• Nectins
• enfortumab vedotin

Topics

• Antibodies, Monoclonal (adverse effects)
• Carcinoma, Transitional Cell (drug therapy)
• Humans
• Immunoconjugates (adverse effects)
• Nectins
• Urinary Bladder Neoplasms (pathology)